

## Personal Information

Melanoma Institute Australia  
40 Rocklands Road  
North Sydney NSW 2060

Phone (W): 9911 7258

Email: alexander.menzies@sydney.edu.au

## Medical Employment

2018-Current Associate Professor Melanoma Medical Oncology, The University of Sydney  
2014-Current Medical Oncologist, Royal North Shore and Mater Hospitals  
2012-Current Medical Oncologist, Melanoma Institute Australia  
2015-2017 CINSW Senior Research Fellow, The University of Sydney  
2012-2014 Doctor of Philosophy (PhD)  
2011 Medical Oncology Clinical Trials Fellow  
2009-10 Medical Oncology Advanced Trainee Registrar  
2008 General Medicine Advanced Trainee Registrar  
2004-7 Internship, Residency, Internal Medicine Registrar (BPT)

## Medical Education

BSc(Med), MBBS with Honours  
The University of New South Wales and St Vincent's Hospital, Australia 1998-2003

## Professional Development and Achievements

### *Grants/Scholarships*

2020 Melanoma Research Alliance (MRA) - Predictors of response to neoadjuvant therapy in melanoma (US\$900,000)  
2020-2024 MRFF grant – Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION) (\$3,230,670)  
2019-2021 CCNSW project grant - Personalised Immunotherapies: Clinical implementation of genomic and transcriptomic biomarkers of response to stratify cancer patients for precision medicine (\$425,095)  
2018-2020 CCNSW project grant - The Role of Tumour-Resident CD8+ T cells in Metastatic Melanoma and Immunotherapy (\$448,374)  
2017-2020 NHMRC project grant - Determinants of response to immune checkpoint inhibitors in melanoma (\$1,021,486)  
2017-2020 NHMRC project grant - Acquired resistance to PD1 inhibition in melanoma (\$986,348)  
2017-2019 CCNSW project grant - Nutrient stress-mediated adaptive responses as novel targets in BRAF mutant melanoma (\$449,174)  
2015 North Sydney Cancer Centre Cancer Immunotherapy Nurse Pilot Study Research Grant (\$150,000)  
2015-2020 Cancer Institute New South Wales (CINSW) Early Career Fellowship x2 (\$450,000)  
2013 Pfizer Australia Cancer Research Grant (\$50,000)  
2012-14 The University of Sydney Australian Postgraduate Award Scholarship (\$71,000)

### *Awards*

2020 Clarivate Web of Science – Highly Cited Researcher (top 1% researcher in the world in 2020 by citation)  
2019 Sydney Research Awards – Young Researcher Award  
2018 NSW Premier's Awards – Outstanding Cancer Research Fellow (less than 5 years)  
2017 NSW Premier's Awards – Wildfire award (highest cited paper), Translational Cancer Research award (research group)

### *Leadership/Academic work*

2020-Current Steering Committee: Society for Melanoma Research  
2019-Current Chair: COSA Melanoma & Skin Cancer Group  
2019-Current Chair: Department of Cancer Medicine, Mater Hospital  
2019-Current Editorial Board: Immuno-Oncology Technology (ESMO)  
2018-Current Faculty member: ESMO Tumour Immunology & Immunotherapy track (2018-2020), Investigational Immunotherapy track (2021-2025)  
2018-Current Clinical Trial Working Group Lead: International Neoadjuvant Melanoma Consortium (INMC)  
2017-Current Faculty, Research Committee and Clinical Committee member: Melanoma Institute Australia  
2016-Current Principal investigator, steering committee and data safety monitoring board member: Phase 1-3 clinical trials  
2016-Current Steering committee: COSA trainees weekend 2020, MSD CTIO 2019, World Congress on Cancers of Skin 2018, ESMO Asia 2017, World Melanoma Congress 2017, COSA ASM 2017, MOGA I-O forum 2016-19, BMS I-O forum 2016  
2015-Current External grants reviewer: NHMRC, National Institute for Health Research (UK), Cancer Research UK  
2015-Current Pillar 2 Lead: Sydney Vital Translational Cancer Research Network  
2013-Current Expert contributor: Cancer Council Australia Clinical Guidelines Melanoma, ESMO Handbook Immuno-Oncology, British Medical Journal Best Practice, and eviQ guidelines  
2012-Current External reviewer: The Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research, Annals of Oncology, European Journal of Cancer, Pigment Cell & Melanoma Research

### *Teaching*

2017-Current Supervision of PhD and Masters candidates, USYD and MIA  
2008-Current Mentoring and supervision of RNSH basic and advanced trainees, MIA fellows and laboratory research staff

### *Memberships*

2011-Current Royal Australasian College of Physicians (RACP), Medical Oncology Group of Australia (MOGA), Clinical Oncology Society of Australia (COSA), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Melanoma and Skin Cancer Trials (MASC), Breast Cancer Trials (BCT), Sydney Vital, Sydney Catalyst

## Accepted/Online

1. Turner RM, Dieng M, Khanna N, Nguyen M, Zeng J, Nijhuis AAG, Nieweg OE, Einstein AJ, Emmett L, Lord SJ, **Menzies AM**, Thompson JF, Saw RPM, Morton RL. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma. Accepted Ann Surg Oncol, **2021**
2. Smith AL, Watts CG, Robinson S, Schmid H, Goumas C, Mar VJ, Thompson J, Rapport F, Braithwaite J, Gyorki DE, Henderson M, Hong AM, Kelly JW, Long GV, **Menzies AM**, Morton RL, Saw RPM, Scolyer RA, Spillane AJ, Mann GJ, Cust AE. Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. Accepted Australasian Journal of Dermatology, **2020**.

## Published

3. **Menzies AM**, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini A, Burton EM, Pennington T, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. **2021**; 27:301-309.
4. Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Griepink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'Ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkoven R, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt W, Peeper DS, Spillane AJ, van Akkooi ACJ, Scolyer RA, Schumacher TNM, **Menzies AM**, Long GV, Blank CU. Survival and Biomarker Analyses from the OpACIN-neo and OpACIN Neoadjuvant Immunotherapy Trials in Stage III Melanoma. Nat Med. **2021**; 27:256-263.
5. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, **Menzies AM**, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. **2021**; 9:e001931
6. Lau B, **Menzies AM**, Joshua AM. Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report. Ann Oncol. **2021**; 32:280-282.
7. Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, Lo S, Carlino MS, Palendira U, Scolyer RA, Long GV, **Menzies AM**. Clinicopathologic characteristics and management of colitis with anti-PD-1 immunotherapy alone or in combination with ipilimumab. J Immunother Cancer. **2020**; 8:e001488.
8. Clark ME, Rizos H, Pereira MR, McEvoy AC, Marsavela G, Calapre L, Meehan K, Ruhen O, Khattak MA, Meniawy TM, Long GV, Carlino MS, **Menzies AM**, Millward M, Ziman M, Gray ES. Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget. **2020**; 11:4016-4027.
9. Hong AM, Waldstein C, Shivalingam B, Carlino MS, Atkinson V, Kefford RF, McArthur GA, **Menzies AM**, Thompson JF, Long GV.. Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. Eur J Cancer. **2021**; 142:10-7.
10. Bhav P, Pallan L, Long GV, **Menzies AM**, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. Br J Cancer. **2021**; 124:574-580.
11. Haanen J, Ernstoff MS, Wang Y, **Menzies AM**, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M. Re-challenge patients with immune checkpoint inhibitors following severe immune-related adverse events: Review of the literature and suggested prophylactic strategy. J Immunother Cancer. **2020**; 8(1).
12. Chatterton S, William S, Nahar K, **Menzies AM\***, Wong MG\*. Immunotherapy related acute kidney injury: Kidney biopsy or not? Nephrology **2021**; 26:89-90.
13. Marsavela G, Lee J, Calapre L, Wong SQ, Pereira MR, McEvoy AC, Reid AL, Robinson C, Warburton L, Abed A, Khattak MA, Meniawy TM, Dawson SJ, Sandhu S, Carlino MS, **Menzies AM**, Scolyer RA, Long GV, Amanuel B, Millward M, Ziman MR, Rizos H, Gray ES. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clin Cancer Res. **2020**; 26:5926-5933.
14. Shklovskaya E LJ, Lim SY, Stewart A, Pedersen B, Ferguson P, Saw RP, Thompson JF, Shivalingam B, Carlino MS, Scolyer RA, **Menzies AM**, Long GV, Kefford RF, Rizos H. Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. Cancers. **2020**; 12:3374.
15. Dieng M, Khanna N, Nguyen MTH, Turner R, Lord SJ, **Menzies AM**, Allen J, Saw R, Nieweg OE, Thompson J, Morton RL. Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. BMJ Open. **2020** Nov 5;10(11):e037857.
16. Krishnan T, **Menzies AM**, Roberts-Thomson R. Applying adjuvant therapy for melanoma into clinical practice. Krishnan T, **Menzies AM**, Roberts-Thomson R. Applying adjuvant therapy for melanoma into clinical practice. Accepted Expert Rev Anticancer Ther. **2020**; 1;1-5.
17. Edwards J, Ferguson PM, Lo SN, Pires da Silva I, Colebatch AJ, Lee H, Saw RPM, Thompson JF, **Menzies AM**, Long GV, Newell F, Pearson JV, Waddell N, Hayward NK, Johansson PA, Mann GJ, Scolyer RA, Palendira U, Wilmott JS. Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunol Res. **2020**; 8:1346-1353.
18. Hultin S, Nahar K, **Menzies AM**, Long GV, Fernando SL, Atkinson V, Cebon J, Wong MG. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrol. **2020**; 21:391
19. Fuchs TL, Pearson A, Pickett J, Diakos C, Dewar R, Chan D, Guminski A, **Menzies AM**, Baron-Hay S, Sheen A, Sioson L, Chou A, Gill AJ. Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. Pathology, **2020**; 52:515-521.
20. Diefenbach RJ, Lee JH, **Menzies AM**, Carlino MS, Long GV, Saw RPM, Howle JE, Spillane AJ, Scolyer RA, Kefford RF, Rizos H. Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. Cancers. **2020**; 12:2228
21. Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, **Menzies AM**, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu L, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. **2020**; 31:1569-1579.
22. Sasson SC, Zaunder JJ, Nahar K, Munier M-L, Fairfax BP, Danielli S, Olsson-Brown A, Jolly C, Read SA, Ahlensteil G, Palendira U, Scolyer RA, Carlino MS, Payne MJ, Cheung VTF, Gupta T, Klenerman P, Long GV, Brain O, **Menzies AM\***, Kelleher AD\*. High levels of mucosal-associated invariant T (MAIT) cell activation occurs in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis. Clin Exp Immunol. **2020**; 202:335-352.
23. Smith A, Shaghayegh G, **Menzies AM**, Roberts-Thomson R. Duration of immunotherapy - should we continue ad infinitum? Intern Med J. **2020**; 50:865-8.
24. Carlino MS, **Menzies AM**, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu W-J, Hodi FS, Guminski AD, Kefford R, Wu H, Ibrahim N, Moreno BH, Long GV. Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Can Res. **2020**; 26:5086-5091.
25. Ziemys A, Kim MS, **Menzies AM**, Wilmott JS, Long GV, Scolyer RA, Kwong LN, Holder AM, Boland GM. Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density with Clinical Response to BRAF Inhibitors in metastatic melanoma. Front Oncol. **2020**; 10:757.

26. Spillane AJ, **Menzies AM**, van Akkooi ACJ. Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – a potential paradigm shift in management. *Ann Surg Oncol*, **2020**; 27:2188-2200.
27. Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, **Menzies AM\***, Long GV\*. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. *Ann Oncol*, **2020**; 31:1075-1082.
28. Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Wilmott JS, **Menzies AM**, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL, Smyth MJ. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. *Clin Can Res*, **2020**; 26:3671-3681.
29. Lee JH, **Menzies AM**, Carlino MS, McEvoy AC, Sandhu S, Weppler AM, Diefenbach RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili Z, Tra T, Gray ES, Wong SQ, Scolyer RA, Long GV, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. *Clin Cancer Res*. **2020**; 26:4064-4071.
30. Tie EN, Lai-Kwon J, Rtshiladze MA, Na L, Bozzi J, Read T, Atkinson V, Au-Yeung G, Long GV, McArthur GA, Sanhu S, Saaw RPM, Walpole E, **Menzies AM**, Smithers BM, Gyorki DG. Efficacy of immune checkpoint inhibitors for in-transit melanoma. *J Immunother Cancer*, **2020**; 8(1).
31. Lee JH, Shklovskaya E, Lim SY, Carlino MS, **Menzies AM**, Stewart A, Pedersen B, Irvine M, Alavi S, Yang JYH, Strbenac D, Saw RPM, Thompson JF, Wilmott JS, Scolyer RA, Long GV, Kefford RF, Rizos H. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. *Nat Commun*, **2020**; 11:1897.
32. Muir CA, **Menzies AM**, Clifton-Bligh R, Tsang VHM. Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer. *Thyroid*, **2020**; 30:1458-1469.
33. Pirozyan MR, McGuire HM, Emran AA, Tseng H, Tiffen J, Lee J, Carlino MS, **Menzies AM**, Long GV, Scolyer RA, Fazekas De St Groth B, Hersey P. Pretreatment Innate cell populations and CD4 T cells in blood are associated with response to immune checkpoint blockade in melanoma patients. *Front Immunol*, **2020**; 11:372.
34. Haanen J, Ernstoff MS, Wang Y, **Menzies AM**, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and Personalized risk-based prevention strategy. *Ann Oncol*. **2020**; 31:724-744.
35. Tsang VT, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, **Menzies AM**. Response to Letter to the Editor for "Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes". *J Clin Endocrinol Metab*. **2020**; 105.
36. Wang DY, McQuade JL, Rai RR, Park JJ, Zhao S, Ye F, Beckerman KE, Rubinstein SM, Johnpulle R, Lobg GV, Carlino MS, **Menzies AM**, Davies MA, Johnson DB. The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. *Oncologist*, **2020**; 25:e602-605.
37. Gide TN, Silva IP, Quek C, Ahmed T, **Menzies AM**, Carlino MS, Saw RPM, Thompson JF, Batten M, Long GV, Scolyer RA, Wilmott JS. Close Proximity of Immune and Tumor Cells Underlies Response to Anti-PD-1 Based Therapies in Metastatic Melanoma Patients. *Oncoimmunology*, **2020**; 9:1659093.
38. Haydu LE, Lo S, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza I, Tawbi H, Carlino MS, **Menzies AM**, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative incidence and predictors of central nervous system metastasis for AJCC 8th edition stage III melanoma patients. *J Clin Oncol*, **2020**; 38:1429-1441.
39. Xu W, Atkinson V, **Menzies AM**. Intratumoural Immunotherapies in Oncology. *Eur J Cancer*, **2020**; 127:1-11.
40. Diefenbach RJ, Lee JH, Strbenac D, Yang JYH, **Menzies AM**, Carlino MS, Long GV, Spillane AJ, Stretch JR, Saw RPM, Thompson JF, Ch'ng S, Scolyer RA, Kefford RF, Rizos H. Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. *Cancers*, **2019**; 11(12).
41. Nijhuis AAG, Spillane AJ, Stretch JR, Saw RPM, **Menzies AM**, Uren RF, Thompson JF, Nieweg OE. Current management of patients with melanoma who are found to be sentinel node-positive. *ANZ J Surg*, **2020**; 90:491-496.
42. Livingstone A, Agrawal A, Stockler MR, **Menzies AM**, Howard K, Morton RL. Preferences for immunotherapy in melanoma: a systematic review. *Ann Surg Oncol*, **2020**; 27:571-84.
43. Mason R, Dearden HC, Nguyen B, Oon JS, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S, Haydon A, Long GV, Carlino MS, Millward M, Atkinson VG\*, **Menzies AM\***. Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. *Pig Cell Mel Res*, **2020**; 33:358-365.
44. Pires da Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, Long GV, **Menzies AM**. Site-specific response patterns, pseudoprogression and acquired resistance in melanoma patients treated with ipilimumab combined with anti-PD-1 therapy. *Cancer*, **2020**; 126:86-97.
45. Diefenbach RJ, Lee JH, Chandler D, Wang Y, Pflueger C, Long GV, Scolyer RA, Carlino MS, **Menzies AM**, Kefford RF, Rizos H. Hypermethylation of circulating free DNA in cutaneous melanoma. *Applied Sciences*. **2019**; 9:5074.
46. Menzer C, **Menzies AM**, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. *J Clin Oncol*, **2019**; 37:3142-51.
47. Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo S, Haydu LE, Vardy JL, Nowak AK, Dhillon HM, Ahmed T, Shivalingam B, Long GV, **Menzies AM**, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, Scolyer RA, Morton RL, Thompson JF. Adjuvant whole brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicentre, randomised phase 3 trial. *J Clin Oncol*, **2019**; 37:3132-41.
48. Johnson DB, McDonnell WJ, Ericsson-Gonzalez PI, Al-Rohil R, Mobley BC, Salem J-E, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem J, **Menzies AM**, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger S, Rushing E, Buchbinder E, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM. Clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. *Nat Med*, **2019**; 25:1243-50.
49. Amaria RN\*, **Menzies AM\***, Burton EM\*, Scolyer RA\*, Tetzlaff MT\*, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty K, Gershenwald JE, Hamid O, Hong A, Kirkwood J, Lo S, Margolin K, Messina J, Postow M, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, Ascierto PA\*, Spillane AJ\*, van Akkooi ACJ\*, Wargo JA\*, Blank CU\*, Tawbi HA\*, Long GV\*. Shaping the Future of Neoadjuvant Systemic Therapy in Melanoma: Recommendations of the International Neoadjuvant Melanoma Consortium (INMC). *Lancet Oncol*, **2019**; 20:e378-e89..
50. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Jakrot V, Scolyer RA, Guminski AD, Long GV, **Menzies AM**. Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes. *J Clin Endocrinol Metab*, **2019**; 104:5499-506
51. Long GV, Saw RPM, Lo S, Nieweg S, Shannon K, Gonzalez M, Guminski A, Lee J, Lee H, Wilmott H, Thompson JF, Kefford RF, Ch'ng S, Stretch J, Emmett L, Rizos H, Spillane A, Scolyer RA, **Menzies AM**. Phase 2 study of neoadjuvant dabrafenib combined with trametinib for resectable stage IIb/c BRAFV600 mutation positive melanoma; the NeoCombi Trial. *Lancet Oncol*, **2019**; 20:961-971.
52. Rozeman EA, **Menzies AM**, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijnsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, ter Meulen S, Koenen AM, Bosch LJ, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Emanuelsson H, Griepink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peepers DS, Spillane AJ, Hansson J, Schmacher TN, Long GV, Blank CU. Identification of the optimal combination scheme of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma: a multicentre randomised phase 2 study (OpACIN-neo). *Lancet Oncol*, **2019**; 20:948-960.

53. Jansen YJL, Rozeman L, Mason R, Goldinger S, Geukes Foppen MH, Hojebegrs L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Makela SP, Seremet T, Arance A, Dummer R, Basholt L, Nyakas MS, Straume O, **Menzies AM**, Long GV, Atkinson V, Blank CU, Neyns B. Clinical Outcome of advanced melanoma patients after discontinuation of an anti-PD-1 antibody in the absence of disease progression or treatment limiting toxicity. *Ann Oncol*, **2019**; 30:1154-61.
54. Nijhuis AAG, Dieng D, Khanna N, Lord SJ, Dalton J, **Menzies AM**, Turner R, Allen J, Saw RPM, Nieweg OE, Thompson JF, Morton RL. False Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. *Ann Surg Oncol*, **2019**; 26:1860-8.
55. Lee JH, Saw RPM, Thompson JF, Lo S, Spillane AJ, Shannon KF, Howle J, **Menzies AM**, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H. Pre-operative ctDNA predicts survival in high risk stage III cutaneous melanoma patients. *Ann Oncol*, **2019**; 30:815-22.
56. Lebbe C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, **Menzies AM**, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. *J Clin Oncol*, **2019**; 37:867-875.
57. Edwards J, Tasker A, Silva I, Quek C, Batten M, Allanson B, Saw RPM, Thompson JF, **Menzies AM**, Palendira U, Wilmott JS, Long GV, Scolyer RA. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve human melanoma: implications for clinical trials. *Clin Cancer Res*, **2019**; 25:3247-58.
58. Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass D, Goldinger SM, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson V, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang T, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB\*, **Menzies AM**\*. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. *Pigment Cell Melanoma Res*, **2019**; 32:553-63.
59. Gide TN, Quek C, **Menzies AM**, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Pires da Silva I, Batten M, Scolyer RA, Long GV, Wilmott JS. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. *Cancer Cell*, **2019**; 35:238-55.
60. Lee H, Quek C, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, **Menzies AM**, Long GV, Scolyer RA, Wilmott JS. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. *Oncoimmunology*, **2018**; 8:e1537581.
61. Kim HY, Duong JK, Gonzalez M, Long GV, **Menzies AM**, Rizos H, Lim SY, Lee J, Boddy AV. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. *Cancer Chemother Pharmacol*, **2019**; 83:693-704.
62. Silva IP, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson D, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang J, Long GV, **Menzies AM**. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. *Clin Can Res*, **2018**; 25:1272-1279.
63. Gide T, Allanson BM, **Menzies AM**, Ferguson PM, Madore J, Saw RPM, Thompson JF, Long GV, Wilmott JS, Scolyer RA. Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment. *Histopathology*, **2019**; 74(6):817-28.
64. Saab KR, Mooradian M, Wang DY, Chon J, Xia CY, Bialczak A, Abbate K, **Menzies AM**, Johnson DB, Sullivan RJ, Shoushtari AN. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have previously received PD-1 based therapy. *Cancer*, **2018**; 125:884-891.
65. Lim SY, Lee LH, Gide T, **Menzies AM**, Guminski A, Carlino MS, Breen E, Yang J, Ghazanfar S, Kefford RF, Scolyer RA, Long GV, Rizos H. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. *Clin Can Res*, **2018**; 25:1557-1563.
66. Tio M, Rai R, Ezeole MO, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellman MD, Long GV, **Menzies AM**. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV, or hepatitis B/C infection. *Eur J Cancer*, **2018**; 104:137-144.
67. Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, **Menzies AM**, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal toxicities from immune checkpoint inhibitors. *JAMA Oncol*, **2018**; 4:1721-1728.
68. Wang KYX, **Menzies AM**, Silva IP, Wilmott JS, Yan Y, Wongchecho M, Kefford RF, Scolyer RA, Long GV, Tarr G, Mueller S, Yang JYH. bcGST - an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. *Bioinformatics*, **2019**; 35:1350-7.
69. Wilmott JS, Johansson PA, Newell F, Waddell N, Ferguson P, Quek C, Patch A-M, Nones K, Shang P, Pritchard AL, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Qinying, Saw RPM, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, **Menzies AM**, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. *Int J Cancer*, **2019**; 144:1049-1060.
70. Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, Guminski AD, Long GV, **Menzies AM**. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. *Ann Oncol*, **2018**; 29:2115-2120.
71. Long GV, Atkinson V, Hong A, McArthur GA, **Menzies AM**. Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation – Authors' reply. *Lancet Oncol*, **2018**; 19:e367.
72. Tetzlaff MT, Messina JL, Stein JE, Amaria RN, Blank C, Van De Wiel B, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, **Menzies AM**, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathologic assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol*, **2018**; 29:1861-8.
73. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss S, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea G, Ecker BL, Fane M, Allegranza MJ, Svornos N, Kumar V, Wang D, Somasundaram R, Hu-Lieskovan S, Herlyn M, Conejo-Garcia JR, Gabrilovich DI, Stone EL, Nowicki TS, Sosman JA, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, **Menzies AM**, McQuade JL, Johnson DB, Osman I, Werraratna AT. Age-related differences in intra-tumoral Tregs dictate response to anti-PD1. *Accepted Clin Can Res*, **2018**.
74. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss S, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea G, Ecker BL, Fane M, Allegranza MJ, Svornos N, Kumar V, Wang D, Somasundaram R, Hu-Lieskovan S, Herlyn M, Conejo-Garcia JR, Gabrilovich DI, Stone EL, Nowicki TS, Sosman JA, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, **Menzies AM**, McQuade JL, Johnson DB, Osman I, Werraratna AT. Age-related differences in intra-tumoral Tregs dictate response to anti-PD1. *Clin Can Res*, **2018**; 24:5347-5356.
75. Long GV, Atkinson V, Lo S, Guminski AD, Sandhu S, Brown MP, Wilmott J, Edwards J, Gonzalez M, Scolyer RA, **Menzies AM**\*, McArthur GA\*. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicenter randomized phase 2 study. *Lancet Oncol*, **2018**; 19:672-81.
76. Edwards J, Wilmott JS, Madore J, Nur Gide T, Quek C, Hewavisenti R, Hersey P, Weninger W, Britton WJ, Saw RPM, Thompson JF, **Menzies AM**, Long GV, Scolyer RA, Palendira U. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naïve melanoma patients and response to anti-PD1 immunotherapy. *Clin Can Res*, **2018**; 24:3036-45.
77. McQuade J, Daniel CR, Hess K, Mak C, Wang DY, Rai R, Park J, Haydu L, Spencer C, Wongchenko M, Lane S, Lee D-Y, Kaper M, McKean M, Beckermann K, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo J, Gershenwald J, Lee J, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob J-J, Flaherty KT, Walker D, Yan Y, McKenna E, Legos J, Carlino M, Ribas A, Kirkwood J, Long G, Johnson DB, **Menzies AM**, Davies MA. Increased BMI is associated with improved outcomes with targeted and immune therapies in patients with metastatic melanoma. *Lancet Oncol*, **2018**; 19:310-322.

78. Lee JH, Long GV, **Menzies AM**, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. *JAMA Oncol*, **2018**; 4:717-21.
79. De Sousa SMC, Sheriff N, Tran CH, **Menzies AM**, Tsang VHM, Guminski AD, Long GV, Tonks KTT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. *Pituitary*, **2018**; 21:274-282.
80. Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, **Menzies AM**, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu Wen, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Re-challenge with BRAF directed treatment in metastatic melanoma: a multi-institutional retrospective study. *Eur J Cancer*, **2018**; 91:116-124.
81. Tio M, Wang X, Carlino MS, Shivalingam B, Fogarty GB, Guminski AD, Lo S, Hong A, **Menzies AM**, Long GV. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. *Pig Cell Mel Res*, **2018**; 31:509-515.
82. Scott E, Long GV, Guminski A, Clifton-Bligh RJ, **Menzies AM**, Tsang VH\*. The Spectrum, Incidence, Kinetics, and Management of Endocrinopathies with Immune Checkpoint Inhibitors for Metastatic Melanoma. *Eur J Endocrinol*, **2018**; 178:175-182.
83. Lee JH, Lyle M, **Menzies AM**, Chan MMK, Lo S, Clements A, Carlino MS, Kefford RF, Long GV. Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. *Pig Cell Mel Res*, **2018**; 31:404-410.
84. Lim SY, Lee J, Welsh S, Ahn SB, Breen E, Khan A, Carlino MS, **Menzies AM**, Kefford RF, Scolyer RA, Long GV, Rizos H. Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. *Biomark Res*, **2017**; 5:32.
85. Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, **Menzies AM**, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. *Ann Oncol*, **2018**; 29:250-255.
86. Sidhu P, **Menzies AM**, Carlino MS, Long GV, Kapoor R. Radiological manifestations of immune related adverse effects observed in patients with melanoma undergoing immunotherapy. *J Med Imaging Radiat Oncol*, **2017**; 61:759-766.
87. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminski A, Long GV, **Menzies AM**. Leptomeningeal melanoma – a case series in the era of modern systemic therapy. *Pig Cell Mel Res*, **2018**; 31:120-124.
88. Thompson JF, **Menzies AM**. Has the melanoma information tsunami become a maelstrom? *Melanoma Manag*, **2017**; 4:179-182.
89. Kakavand H, Jackett LA, **Menzies AM**, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. *Mod Pathol*, **2017**; 30:1666-1676.
90. Gu YF, **Menzies AM**, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following combined checkpoint immunotherapy for metastatic melanoma: a case report and literature review. *J Clin Neurosci* **2017**; 45:14-17.
91. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu W-J, Hodi FS, **Menzies AM**, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Gibbs D, Lomax A, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. *Lancet Oncol*, **2017**; 18:1202-1210.
92. Kakavand H, Rawson RV, Pupo GM, Yang JYH, **Menzies AM**, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. *Clin Can Res*, **2017**; 23:6054-6061.
93. Lim SY, **Menzies AM**, Rizos H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. *Cancer*, **2017**; 123:2118-29.
94. Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, **Menzies AM**, Klein O, Carlino MS. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. *Br J Cancer*, **2017**; 116:1558-1563.
95. Vilain RE, **Menzies AM**, Kakavand H, Madore J, Wilmott JS, Liniker E, Kong B, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. *Clin Can Res*, **2017**; 23:5024-5033.
96. Pupo G, Boyd S, Fung C, Carlino MS, **Menzies AM**, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. *Biomark Res*, **2017**; 5:17.
97. Tan AC, Heimberger AB, **Menzies AM**, Pavlakis NP, Khasraw M. Immune Checkpoint Inhibitors in Brain Metastases. *Curr Oncol Rep*, **2017**; 19:38.
98. **Menzies AM**, Long GV. Optimal dosing of ipilimumab in melanoma: too little, too late? *Lancet Oncol*, **2017**; 18:558-559.
99. Lee JH, Long GV, Boyd SC, Lo S, **Menzies AM**, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H. Circulating tumor DNA predicts response to anti-PD1 antibodies in metastatic melanoma. *Ann Oncol*, **2017**; 28(5):1130-6.
100. Johnson DB, Sullivan RJ, **Menzies AM**. Immune checkpoint inhibitors in challenging populations. *Cancer*, **2017**; 123:1904-11.
101. Choong ES, Lo S, Drummond M, Fogarty GB, **Menzies AM**, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. *Eur J Cancer*, **2017**; 75:169-78.
102. Itchins M, Ascierto PA, **Menzies AM**, Oatley M, Lo S, Harrington T, Maher R, Grimaldi AM, Guminski A. A multi-referral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilisation of sequential liver directed treatment and immunotherapy. *Mel Res*, **2017**; 27:243-250.
103. Liang R, Meiser B, Smith S, Kasparian NA, Lewis CR, Chin M, Long GV, Ward R, **Menzies AM**, Harris-Wai JN, Kaur R. Advanced cancer patients' attitudes toward, and experiences with, screening for somatic mutations in tumours: A qualitative study. *Eur J Cancer Care*, **2017**; 26:e12600.
104. **Menzies AM**, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoustari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol*, **2017**; 28:368-376.
105. Naidoo J, Wang X, Woo KM, Cunningham J, Halpenny D, Chaff JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss M, Rudin CM, Hou X, Rodriguez K, Albano M, Gordon R, Leduc C, Rekhtman N, Iyiboz T, **Menzies AM**, Guminski A, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD. Pneumonitis in Patients treated with Anti-PD-1/PD-L1 Therapy. *J Clin Oncol*, **2017**; 35:709-717.
106. Atkinson V, Long GV, **Menzies AM**, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. *Asia Pac J Clin Oncol*, **2016**; 12 Suppl 7:5-12.
107. Liniker E, **Menzies AM**, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV. Activity and Safety of Radiotherapy with Anti-PD-1 Drug Therapy in Patients with Metastatic Melanoma. *Oncoimmunology*, **2016**; 5:e1214788.
108. Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, **Menzies AM**, Long GV, Ascierto PA. Cessation of targeted therapy after a complete response in BRAF mutant advanced melanoma: a case series. *Br J Cancer*, **2016**; 115:1280-1284.
109. **Menzies AM**, Long GV. Recent Developments in Melanoma Therapy. *JAMA Oncol*, **2016**; 2:1259-1260.
110. Kong BY, **Menzies AM**, Saunderson CAB, Liniker E, Ramanujam S, Guminski A, Kefford RF, Long GV, Carlino MS. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. *Pig Cell Mel Res*, **2016**; 29:572-577.
111. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkova AV, Meeth K, Tang H, Yin X, Wood WH, Lehmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, **Menzies AM**, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. *Nature*, **2016**; 532:250-4.

112. De Paoli-Iseppi, R, Johansson P, **Menzies AM**, Dias K-R, Pupo GM, Kakavand H, Mann GJ, Hayward NK, Dinger ME, Long GV, Scolyer RA, Wilmott JS. Comparison of whole-exome sequencing of matched fresh and formalin-fixed paraffin embedded melanoma tumors: implications for clinical decision making. *Pathology*, **2016**; 48:261-6.
113. Lyle M, Haydu LE, **Menzies AM**, Thompson JF, Saw RPM, Spillane AJ, Kefford RF, Mann GJ, Cooper W, Yu B, Scolyer RA, O'Toole SA, Long GV. The molecular profile of metastatic melanoma in Australia. *Pathology*, **2016**; 48:188-93.
114. Madore J, Strbenac D, Vilain RE, **Menzies AM**, Yang J, Thompson JF, Long GV, Mann G, Scolyer RA, Wilmott JS. PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma. *Clin Can Res*, **2016**; 3915-23.
115. Kong BY, Carlino MS, **Menzies AM**. The biology and treatment of BRAF mutant melanoma. *Melanoma Manag*, **2016**; 3:33-45.
116. Fox P, Balleine RL, Lee C, Gao B, Balakrishnar B, **Menzies AM**, Yeap SH, Ali SS, Gebiski V, Provan, Coulter S, Liddle C, Hui R, Kefford R, Lynch J, Wong M, Wilcken N, Gurney H. Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring - The TADE Study. *Clin Can Res*, **2016**; 22:3164-3171.
117. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Guminski A, Puzanov I, Buchbinder E, Wudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, **Menzies AM**, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab in patients with advanced melanoma and pre-existing autoimmune disorders. *JAMA Oncol*, **2016**; 2:234-40.
118. Johnson DB\*, **Menzies AM**\*, Zimmer L\*, Eroglu Z\*, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger S, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms. *Eur J Cancer*, **2015**; 51:2792-9.
119. **Menzies AM**, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MMK, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. *Cancer*, **2015**; 121:3826-35.
120. **Menzies AM**, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S. Sentinel node biopsy for melanoma: the medical oncology perspective (letter). *Aust Fam Physician*, **2015**; 44:875.
121. Carlos G, Anforth R, Clements A, **Menzies AM**, Carlino MS, Chou S, Fernandez-Penas P. Cutaneous Toxicities of BRAF inhibitors, alone and in combination with MEK inhibitors for metastatic melanoma. *JAMA Dermatol*. **2015**; 151:1103-9.
122. **Menzies AM**, Yeh I, Botton T, Bastian BC, Scolyer RA, Long GV. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. *Pig Cell Mel Res*, **2015**; 28:607-10.
123. Kakavand H, Wilmott JS, **Menzies AM**, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Scolyer RA, Long GV. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. *Clin Can Res*, **2015**; 21:3140-8.
124. Anforth R, **Menzies AM**, Byth K, Carlos G, Chou S, Sharma R, Scolyer R, Kefford R, Long GV, Fernandez-Penas P. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. *J Am Acad Dermatol*, **2015**; 72:809-15.
125. Madore J, Vilain R, **Menzies AM**, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA. PD-L1 expression in melanoma has prognostic significance but shows marked heterogeneity within and between patients- implications for anti PD-1/PD-L1 clinical trials. *Pig Cell Mel Res*, **2015**; 28:245-53.
126. **Menzies AM**, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. *Ann Oncol*, **2015**; 26:415-21.
127. Wang J, Huang SK, Marzese DM, Hsu SC, Kawas NP, Chong KK, Long GV, **Menzies AM**, Scolyer RA, Izraely S, Sagi-Assif O, Witz IP, Morton DL, Hoon DSB. Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. *J Invest Dermatol*. **2015**; 135:532-41.
128. Long GV, Fung C, **Menzies AM**, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw R, Howle J, Hayward NK, Johanson P, Scolyer RA, Kefford RF, Rizos H. Predominance of MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. *Nat Commun*, **2014**; 5:5694.
129. **Menzies AM**, Wilmott JS, Long GV, Scolyer RA. Intra-patient heterogeneity of BRAF mutation status: fact or fiction? *Br J Cancer*, **2014**; 111:1678-9.
130. Zimmer L, Haydu LE, **Menzies AM**, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, Long GV. Reply to m. Perier-muzet et al. *J Clin Oncol*, **2014**; 32:3203-04.
131. Chan MMK, Haydu LE, **Menzies AM**, Azer MWF, Klein O, Lyle M, Clements A, Guminski A, Kefford RF, Long GV. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. *Cancer*, **2014**; 120:3142-3153.
132. **Menzies AM**, Long GV. Systemic treatment for BRAF-mutant melanoma: Where do we go next? *Lancet Oncol*, **2014**; 15:e371-e381.
133. Lee CI\*, **Menzies AM**\*, Haydu LE, Azer M, Clements A, Kefford RF, Long GV. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. *Mel Res*, **2014**; 24:468-474.
134. Lezcano C, Lee C, Larson AR, **Menzies AM**, Kefford RF, Thompson JF, Mihm MC, Ogino S, Long GV, Scolyer RA, Murphy GF. Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. *Mod Pathol*, **2014**; 27: 1193-1202.
135. Carlino MS, Haydu LE, Kakavand H, **Menzies AM**, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. *Br J Cancer*, **2014**; 111:292-99.
136. Ackerman A, Klein O, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Hodi, SF, Ibrahim N, Kefford RF, **Menzies AM**, Atkins MB, Cho DC, Long GV, Sullivan RJ. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. *Cancer*, **2014**; 120:1695-701.
137. **Menzies AM**, Long GV. Dabrafenib and Trametinib, alone and in combination for BRAF-mutant metastatic melanoma. *Clin Can Res*, **2014**; 20:2035-43.
138. Rizos H, **Menzies AM**, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV. BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact. *Clin Can Res*, **2014**; 20:1965-77.
139. Wilmott JS, Haydu LE, **Menzies AM**, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA, Long GV. Dynamics of chemokine and growth factor expression in the serum of BRAF-mutant melanoma patients during BRAF inhibitor treatment. *J Immunol*, **2014**; 192:2505-13.
140. **Menzies AM**, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, O'Toole S, Long GV, Scolyer RA. Inpatient homogeneity of BRAFV600E expression in melanoma. *Am J Surg Path*, **2014**; 38:377-82.
141. Azer MF\*, **Menzies AM**\*, Haydu LE, Kefford RF, Long GV. Patterns of Response and Progression in Patients with BRAF-mutant Melanoma Metastatic to the Brain treated with Dabrafenib. *Cancer*. **2014**; 120:530-6.
142. **Menzies AM**, Haydu LE, Carlino MS, Azer MWF, Carr PJA, Kefford RF, Long GV. Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. *PLoS ONE* **2014**; 9:e85004.
143. Zimmer L, Haydu LE, **Menzies AM**, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, Long GV. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. *J Clin Oncol*, **2013**; 32:816-23.
144. Schramm S-J, **Menzies AM**, Mann GJ. Molecular biomarkers of prognosis in melanoma: how far are we from the clinic? *Mel Res*. **2013**; 23:423-425.
145. **Menzies AM**, Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. *Eur J Cancer* **2013**; 49:3229-4.
146. **Menzies AM**, Long GV. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. *Ther Adv Med Oncol* **2013**; 5:278-285.
147. **Menzies AM**, Kefford RF, Long GV. Paradoxical oncogenesis: are all BRAF inhibitors equal? *Pig Cell Mel Res* **2013**; 26:611-5.

148. Thompson JF\*, **Menzies AM\***: Melanoma. Cancer Forum **2013**; 37:65-66.
149. Wilmott JS\*, **Menzies AM\***, Haydu LE, Capper D, Preusser M, Zhang E, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Long GV. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer **2013**; 49:1073-9.
150. Klein O, Clements A, **Menzies AM**, O'Toole S, Kefford RF, Long GV. BRAF inhibitor activity in V600R metastatic melanoma-response. Eur J Cancer **2013**; 49:1797-8.
151. Klein O, Clements A, **Menzies AM**, O'Toole S, Kefford RF, Long GV. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer **2013**; 49:1073-9.
152. Carlino MS, Saunders CAB, Haydu L, **Menzies AM**, Lebowitz PF, Kefford RF, Long GV. 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Eur J Cancer **2013**; 49:395-402.
153. **Menzies AM**, Long GV, Murali R. The development of dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther **2012**; 6:391-405.
154. **Menzies AM**. Systemic therapy for metastatic melanoma – MAPK inhibitors and immunotherapy. Cancer Forum **2012**; 36:156-61.
155. **Menzies AM**, Long GV. Clinicopathologic features of V600E and V600K melanoma - Response. Clin Can Res **2012**; 18:6793.
156. **Menzies AM**, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing clinicopathologic features of V600E and V600K BRAF-mutant metastatic melanoma. Clin Can Res **2012**; 18:3242-9.
157. Long GV, **Menzies AM**, Nagrial A, Haydu L, Hamilton AL, Mann G, Hughes TM, Thompson JF, Scolyer RA, Kefford R. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol **2011**; 29:1239-46.

### **Selected National and International Conference Presentations**

1. **Menzies AM**. Checkpoint inhibitors in special populations. *Invited Speaker*. ESMO Congress, Barcelona, Spain, **2019**.
2. **Menzies AM**. Melanoma immuno-oncology update. *Invited Speaker*. MOGA Immuno-oncology forum, Canberra, Australia, **2019**.
3. **Menzies AM**, Rozeman EA, Amaria RN, Huang AC, Scolyer RA, Tetzlaff M, van de Wiel BA, Lo S, Tarhini A, Tawbi H, Burton E, Karakousis GC, Ascierto P, Spillane A, Davies M, van Akkooi ACJ, Mitchell T, Long GV, Wargo J, Blank CU Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *Oral Abstract*. ASCO Annual General Meeting, Chicago, USA, **2019**.
4. Pires da Silva I, **Menzies AM**, Newell F, Wilmott JS, Carlino MS, Fergison PM, Edwards J, Spillane A, Shannon K, Saw R, Thompson JF, Rizos H, Mann GJ, Johansson P, Hayward N, Scolyer RA, Waddell N, Long GV. Comprehensive molecular profiling of metastatic melanoma to predict response to anti-PD-1 based immunotherapy. *Oral Abstract*. ASCO Annual General Meeting, Chicago, USA, **2019**.
5. Owen C, Larkin MG, Shoushtari AN, Carlino MS, Blank CU, Lee B, Mangana J, Atkinson V, Millward M, Zaman F, Young A, Khattak MA, Patel SP, Hoeller C, Hersey P, Chauhan D, Palmieri DJ, Lo S, **Menzies AM**, Long GV. A multicenter analysis of melanoma recurrence following adjuvant anti-PD1. *Oral Abstract*. ASCO Annual General Meeting, Chicago, USA, **2019**.
6. Silva I, Tasker A, Quek C, Rawson R, Lim SY, Wang K, Conway J, Velickovic, Ahmed T, Lo S, Yang J, Rizos H, Wilmott JS, Scolyer RA, **Menzies AM**, Long GV. Liver metastases induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma. *Oral Abstract*. AACR Congress, Atlanta, USA, **2019**.
7. Gide TN, Quek C, **Menzies AM**, Tasker AT, Shang P, Holst J, Madroe J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Silva I, Pang A, McGuire HM, Palendira M, Thompson JF, Rizos H, Batten M, Scolyer RA, Long GV, Wilmott JS. EOMES+CD45RO+ effector memory T-cells determine response to anti-PD-1 based immunotherapies. *Oral Abstract*. SMR Congress, Manchester, UK, **2018**.
8. **Menzies AM**. Systemic therapies for loco-regional metastases. *Invited Speaker*. Australasian Melanoma Conference, Melbourne, Australia, **2018**.
9. **Menzies AM**. Adjuvant systemic therapy for high-risk melanoma. *Invited Speaker*. World Congress on Cancers of the Skin, Sydney, Australia, **2018**.
10. **Menzies AM**. Poster discussant. Combination treatment for advanced melanoma. *Invited Speaker*. ASCO Annual General Meeting, Chicago, USA, **2018**.
11. Tan AC, Emmett L, Lo S, Liu V, Guminski AD, Long GV, **Menzies AM**. Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM). *Poster Discussion*. ASCO Annual General Meeting, Chicago, USA, **2018**.
12. Gide TN, Quek C, **Menzies AM**, Madore J, Velickovic R, Shang P, Wongchenko M, Yan Y, Carlino MS, Guminski A, Saw RPM, Silva I, Palendira U, Thompson JF, Scolyer RA, Long GV, Wilmott JS. Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance. *Poster Discussion*. ASCO Annual General Meeting, Chicago, USA, **2018**.
13. **Menzies AM**. Integrating research into Early phase trials in Melanoma. *Invited Speaker*. Drug Development Conference, Sydney, Australia, **2018**.
14. **Menzies AM**. Toxicity management and IO drugs in non-trial populations. *Invited Speaker*. ESMO Asia Congress, Singapore, **2017**.
15. **Menzies AM**. Treating non-trial populations. *Invited Speaker*. COSA Annual Scientific Meeting, Sydney, Australia, **2017**.
16. **Menzies AM**. New cancer treatments: Immunotherapy. *Invited Speaker*. COSA Public Forum, Sydney, Australia, **2017**.
17. **Menzies AM**, Long GV, Atkinson V, Lo S, Guminski A, Brown MP, Gonzalez M, Diamante K, Shandhu S, Scolyer RA, Emmett L, McArthur G. A Randomized Phase 2 Study of Nivolumab or Nivolumab plus Ipilimumab in Patients with Melanoma Brain Metastases: The Anti-PD1 Brain Collaboration (ABC). *Oral Abstract*. SMR Congress, Brisbane, Australia, **2017**.
18. **Menzies AM**. Designing trials and selecting endpoints in the era of combination systemic treatment of melanoma. *Invited Speaker*. SMR Congress, Brisbane, Australia, **2017**.
19. **Menzies AM**, Gonzalez M, Guminski A, Nieweg O, Shannon K, Thompson JF, Kefford RF, Ch'Ng S, Stretch J, Spillane AJ, Lee J, Lee H, Kapoor R, Emmett L, Rizos H, Saw RPM, Scolyer RA, Long GV. Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma. *Poster Discussion*. ESMO Congress, Madrid, Spain, **2017**.
20. Rai R, Ezeoke OM, McQuade JL, Zimmer L, Koo C, Park JJ, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Hellman MD, Long GV, **Menzies AM**. PD-1/PD-L1 immunotherapy in patients with HIV, hepatitis B/C, or solid organ transplant. *Poster Discussion*. ESMO Congress, Madrid, Spain, **2017**.
21. **Menzies AM**. Can we treat patients with pre-existing autoimmune diseases? *Invited Speaker*. MOGA Immuno-Oncology Forum, Melbourne, Australia, **2017**.
22. **Menzies AM**. Oral abstract discussant. Long term survival: What do we know? *Invited Speaker*. ASCO Annual General Meeting, Chicago, USA, **2017**.
23. Long GV, Atkinson V, **Menzies AM**, Lo S, Guminski AD, Brown MP, Gonzalez MM, Diamante K, Sandhu SK, Scolyer RA, Emmett L, McArthur GA. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). *Oral Abstract*. ASCO Annual General Meeting, Chicago, USA, **2017**.
24. Da Silva IEDP, Johnpulle RAN, Banks PD, Grass GD, Smith JL, Everett AS, Goldinger SM, Roberts-Thomson R, Millward M, Glitza IC, Haydu LE, Atkinson V, Wang T, Eroglu Z, Conry RE, Shackleton MJ, Hong A, Long GV, Johnson DB, **Menzies AM**. Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). *Poster Discussion*. ASCO Annual General Meeting, Chicago, USA, **2017**.
25. **Menzies AM**. Optimizing melanoma treatment in 2017. *Invited Speaker*. Current Trends in Immuno-Oncology, Sydney, Australia, **2017**.
26. **Menzies AM**. Melanoma Case Discussion. *Invited Speaker*. Haematology and Oncology Targeted Therapies Annual Meeting, Sydney, Australia, **2017**.
27. **Menzies AM**. Management of Immunotherapy Toxicity. *Invited Speaker*. COSA Annual Scientific Meeting, Gold Coast, Australia, **2016**.
28. **Menzies AM**. Adjuvant systemic therapy in melanoma. *Invited Speaker*. Australasian Melanoma Conference, Sydney, Australia, **2016**.
29. Arasaratnam M, Wheeler H, Hong A, Guminski A, Long GV, **Menzies AM**. Leptomeningeal melanoma – a case series in the IIB of modern systemic therapy. *Oral Abstract*. Australasian Melanoma Conference, Sydney, Australia, **2016**.

30. Tio M, Wang X, Carlino MS, Shivalingham B, Fogarty GB, Guminski AD, Lo S, Hong A, **Menzies AM**, Long GV. Survival and prognostic factors of metastatic melanoma patients with brain metastases. **Oral Abstract**. Australasian Melanoma Conference, Sydney, Australia, **2016**.
31. Park JJ, Parakh S, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, **Menzies AM**, Klein O, Carlino MS. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. **Poster Discussion**. ESMO Congress, Copenhagen, Denmark, **2016**.
32. Rai R, Nahar K, Park JJ, McQuade JL, Wang D, Beckermann K, Rubinstein S, Sosman JA, McKean M, Haydu LE, Lo S, Guminski A, Carlino MS, Davis MA, Johnson DB, Long GV, **Menzies AM**. Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma. **Poster Discussion**. ESMO Congress, Copenhagen, Denmark, **2016**.
33. **Menzies AM**. Clinical Problems in Oncology - Real-World Issues Using Immunotherapy and Targeted Therapies in Melanoma. **Invited Speaker**. ASCO Annual General Meeting, Chicago, USA, **2016**.
34. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu W-J, Hodi FS, **Menzies AM**, Guminski AD, Kefford R, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. **Oral Abstract**. ASCO Annual General Meeting, Chicago, USA, **2016**.
35. **Menzies AM**, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoustari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). **Poster Discussion**. ASCO Annual General Meeting, Chicago, USA, **2016**.
36. **Menzies AM**. Adjuvant systemic therapy for melanoma. **Invited Speaker**. Australasian Skin Cancer Congress, Gold Coast, Australia, **2016**.
37. **Menzies AM**. Immunotherapy & Melanoma: General principles and common toxicities. **Invited Speaker**. COSA Advanced Trainees in Oncology Meeting, Sydney, Australia, **2016**.
38. Welsh SJ, Boyd S, McGuire H, Gonzales M, **Menzies AM**, Kakavand H, James E, Smith E, Fazekas B, Guminski A, Kefford RF, Scolyer RA, Long GV, Rizos H. In depth profiling of the response of melanoma to MAPK inhibition. **Oral Abstract**. AACR Annual Meeting. New Orleans, USA, **2016**.
39. Long GV, Carlino MS, Atkinson V, Cebon J, Jameson M, Fitzharris B, McNeil C, Hill A, Ribas A, Thompson JA, Hwu W-J, Hodi FS, Choueiri TK, **Menzies AM**, Guminski A, Kefford R, Tamjid B, Srivastava A, Gibbs D, Lomax AJ, Shu X, Perini RF, Ibrahim N, Atkins M. KEYNOTE-029: Pembrolizumab + Low-Dose Ipilimumab for Advanced Melanoma. **Oral Abstract**. SMR Congress, San Francisco, USA, **2015**.
40. **Menzies AM**. Immuno-Oncology: Clinical Status Melanoma. **Invited Speaker**. COSA Annual Scientific Meeting, Hobart, Australia, **2015**.
41. **Menzies AM**. Clinical Update: Melanoma. **Invited Speaker**. MOGA Immuno-Oncology forum, Melbourne, Australia, **2015**.
42. Vilain RE, Kakavand H, **Menzies AM**, Madore J, Wilmott J, Dobney R, Jakrot V, Cooper AJ, Kong B, Lo S, Liniker E, Saw RP, Thompson JF, Kefford R, Carlino MS, Long GV, Scolyer RA. PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. **Oral Abstract**. European Cancer Congress, Vienna, Austria, **2015**.
43. Liniker E, Kong B, **Menzies AM**, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV. Safety and Activity of Combined Radiotherapy and Anti-PD1 Antibodies in Patients with Metastatic Melanoma. **Oral Abstract**. European Cancer Congress, Vienna, Austria, **2015**.
44. Kong B, Saunders CAB, Ramanujam S, Guminski A, **Menzies AM**, Kefford RF, Long GV, Carlino MS. Metabolic activity in metastatic melanoma after long-term treatment with anti-PD-1 antibodies. **Oral Abstract**. European Cancer Congress, Vienna, Austria, **2015**.
45. **Menzies AM**. Key advances and developments in melanoma. **Invited Speaker**. MOGA Annual Scientific Meeting, Hobart, Australia, **2015**.
46. Johnson DB, **Menzies AM**, Zimmer L, Eroglu Z, Ye F, Zhao S, Sucker A, Rizos H, Hugo W, Gutzmer R, Kefford RF, Gogas H, Kong X, Scolyer RA, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. **Oral Abstract**. ASCO Annual General Meeting, Chicago, USA, **2015**.
47. **Menzies AM**, Visintin L, Chatfield MD, Carlino MS, Howle JR, Scolyer RA, Thompson JF, Kefford RF. BRAF mutation by age-decade and body mass index in metastatic melanoma. **Oral Abstract**. ASCO Annual General Meeting, Chicago, USA, **2011**.

## **Referees**

Professor Georgina Long  
Professor of Melanoma Medical Oncology and Translational Research, The University of Sydney  
Co-Medical Director Melanoma Institute Australia  
Melanoma Institute Australia and Royal North Shore Hospital  
40 Rocklands Rd North Sydney NSW 2060  
Tel: (02) 9911 7336  
Email: georgina.long@sydney.edu.au

Professor Richard Scolyer  
Clinical Professor, Sydney Medical School, The University of Sydney  
Co-Medical Director Melanoma Institute Australia  
Co-Director of Research, Melanoma Institute Australia  
Dept. of Tissue Pathology & Diagnostic Oncology  
Royal Prince Alfred Hospital  
Missenden Rd Camperdown NSW 2050  
Tel: (02) 9911 7336  
Email: richard.scolyer@sswahs.nsw.gov.au